What BPC-157 is. And where it comes from
BPC-157 is a synthetic 15-amino-acid sequence. Its name. Body Protection Compound, comes from the fact that the parent molecule was first isolated from gastric juice and shown in animal models to be protective of gut tissue under stress. The synthetic version is identical in sequence to the fragment identified in that body of work.
It is small (roughly the size of an average small peptide hormone), water-soluble, and stable enough to be tested in standard laboratory and animal protocols. It is not a protein, not an antibody, and not a steroid.
The preclinical signal is one of local repair orchestration, not systemic anabolic action. A distinction that rarely makes it into online discussion of this compound.
Mechanism, in plain English
The published research points to four tissue-level signals that BPC-157 appears to influence. None of these are settled in humans, but they are consistently reported in the preclinical literature.
Want all 31 muscle recovery compounds in one place?
The Peptexa Muscle Recovery guide covers every compound in this category, mechanism, evidence level, and FDA status for each.
What the preclinical evidence shows
The bulk of the published evidence comes from rodent models, tendon transection and Achilles repair, vascular ligation, NSAID-induced gut damage, and fistulizing colitis models. Effects have been reported as positive in tendocyte outgrowth assays, in vascular angiogenesis assays, and in rat colitis models. The most-cited review is Sikiric (2018) in Current Pharmaceutical Design.
Human published data is limited to small case-series reports and registry submissions. There are no large randomized controlled trials to date. The bulk of the discussion in online health communities reflects animal extrapolation, not human-trial data.
Strong preclinical animal research supports investigation into tendon, ligament, and gastrointestinal healing. Human clinical evidence remains limited despite extensive anecdotal use.
FDA status (this month)
BPC-157 is not FDA-approved for any human indication. On July 23-24, 2026, an FDA Pharmacy Compounding Advisory Committee reviewed several peptides including BPC-157 and voted to recommend reviewing whether compounding pharmacies may be allowed to produce them. A rule-making step would be required before any compounding access is granted. And that step is not FDA approval. Coverage: NYT briefing. Last reviewed 2026-08-09.
Common synonyms researchers use
BPC 157 · BPC-157 · Body Protection Compound 157 · PL-14736 (early proprietary designation in the Sikiric et al. literature).
Safety & adverse-event landscape
In the published preclinical literature, BPC-157 has been administered to rodents over short and medium-term protocols without reported mortality. Adverse-event data in humans is limited. The compound's interaction with nitric oxide pharmacology suggests theoretical considerations with vasodilator and cardiovascular medications, consult your provider if you take any.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision that involves a peptide, supplement, or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Muscle Recovery reference
31 compounds. Mechanism, evidence level, and FDA status for every one. Free PDF, no email required.
Get the Muscle Recovery & Healing Guide →